EP1335707A4 - Nouvelles formulations de carvedilol - Google Patents
Nouvelles formulations de carvedilolInfo
- Publication number
- EP1335707A4 EP1335707A4 EP01273804A EP01273804A EP1335707A4 EP 1335707 A4 EP1335707 A4 EP 1335707A4 EP 01273804 A EP01273804 A EP 01273804A EP 01273804 A EP01273804 A EP 01273804A EP 1335707 A4 EP1335707 A4 EP 1335707A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- carvedilol
- novel formulations
- formulations
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24291100P | 2000-10-24 | 2000-10-24 | |
US242911P | 2000-10-24 | ||
PCT/US2001/050872 WO2002065834A2 (fr) | 2000-10-24 | 2001-10-23 | Nouvelles formulations de carvedilol |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1335707A2 EP1335707A2 (fr) | 2003-08-20 |
EP1335707A4 true EP1335707A4 (fr) | 2005-07-06 |
Family
ID=22916614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01273804A Withdrawn EP1335707A4 (fr) | 2000-10-24 | 2001-10-23 | Nouvelles formulations de carvedilol |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1335707A4 (fr) |
JP (1) | JP2004518734A (fr) |
AU (1) | AU2001297631A1 (fr) |
CA (1) | CA2426811A1 (fr) |
WO (1) | WO2002065834A2 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69917618T2 (de) | 1998-04-03 | 2005-06-23 | Egalet A/S | Zusammensetzung mit kontrollierter wirkstoff-freisetzung |
IN191028B (fr) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
WO2003024430A1 (fr) | 2001-09-21 | 2003-03-27 | Egalet A/S | Systeme a liberation de polymere de morphine |
WO2003024429A1 (fr) | 2001-09-21 | 2003-03-27 | Egalet A/S | Systeme de liberation a base de polymere |
WO2003024426A1 (fr) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Dispersions solides a liberation controlee |
WO2004041252A1 (fr) | 2002-11-08 | 2004-05-21 | Egalet A/S | Compositions de carvedilol a liberation commandee |
EP2301526B1 (fr) | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Système de libération contrôlée de morphine |
DK1610768T3 (da) | 2003-03-26 | 2008-09-22 | Egalet As | Matrikskompositioner til styret afgivelse af lægemiddelsubstanser |
US20050175695A1 (en) * | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
JP5042041B2 (ja) | 2005-02-25 | 2012-10-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 心筋症及び心臓病を処置及び予防するための組成物及び方法 |
HU227490B1 (en) * | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
CN101534843A (zh) | 2006-08-01 | 2009-09-16 | 普里克萨斯医药股份有限公司 | 泊洛沙姆用于预防和/或治疗心力衰竭的用途 |
HU227881B1 (en) * | 2007-02-23 | 2012-05-29 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
WO2008114276A1 (fr) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Nouvelle composition orale de carvédilol à libération contrôlée |
US8372387B2 (en) | 2007-04-05 | 2013-02-12 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
FR2936709B1 (fr) * | 2008-10-02 | 2012-05-11 | Ethypharm Sa | Comprimes alcoolo-resistants. |
WO2010089132A1 (fr) | 2009-02-06 | 2010-08-12 | Egalet A/S | Composition à libération immédiate résistant à une maltraitance par prise d'alcool |
WO2010149169A2 (fr) | 2009-06-24 | 2010-12-29 | Egalet A/S | Formulations à libération contrôlée |
TWI415604B (zh) * | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | 調控釋放卡菲蒂羅劑型 |
MX2014015880A (es) | 2012-07-06 | 2015-08-05 | Egalet Ltd | Composiciones farmaceuticas disuasivas de abuso para liberacion controlada. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816036A1 (de) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen |
WO2000000179A1 (fr) * | 1998-06-27 | 2000-01-06 | Won Jin Biopharma Co., Ltd. | Preparation a dispersion solide d'un medicament faiblement hydrosoluble contenant de l'huile, un acide gras ou leurs melanges |
WO2000004902A1 (fr) * | 1998-07-23 | 2000-02-03 | Roche Diagnostics Gmbh | Solution pour injection de carvedilol stabilise |
WO2000032174A2 (fr) * | 1998-11-27 | 2000-06-08 | F. Hoffmann-La Roche Ag | Specialite pharmaceutique combinee |
WO2001035958A1 (fr) * | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Methane-sulfonate de carvedilol |
WO2001074356A1 (fr) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Solutions concentrees de carvedilol |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
PL335619A1 (en) * | 1997-03-11 | 2000-05-08 | Darwin Discovery Ltd | Dosage forms including separate parts containing r and s enantiomers |
-
2001
- 2001-10-23 CA CA002426811A patent/CA2426811A1/fr not_active Abandoned
- 2001-10-23 AU AU2001297631A patent/AU2001297631A1/en not_active Abandoned
- 2001-10-23 WO PCT/US2001/050872 patent/WO2002065834A2/fr not_active Application Discontinuation
- 2001-10-23 EP EP01273804A patent/EP1335707A4/fr not_active Withdrawn
- 2001-10-23 JP JP2002565411A patent/JP2004518734A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816036A1 (de) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen |
WO2000000179A1 (fr) * | 1998-06-27 | 2000-01-06 | Won Jin Biopharma Co., Ltd. | Preparation a dispersion solide d'un medicament faiblement hydrosoluble contenant de l'huile, un acide gras ou leurs melanges |
WO2000004902A1 (fr) * | 1998-07-23 | 2000-02-03 | Roche Diagnostics Gmbh | Solution pour injection de carvedilol stabilise |
WO2000032174A2 (fr) * | 1998-11-27 | 2000-06-08 | F. Hoffmann-La Roche Ag | Specialite pharmaceutique combinee |
WO2001035958A1 (fr) * | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Methane-sulfonate de carvedilol |
WO2001074356A1 (fr) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Solutions concentrees de carvedilol |
Non-Patent Citations (1)
Title |
---|
See also references of WO02065834A3 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001297631A1 (en) | 2002-09-04 |
EP1335707A2 (fr) | 2003-08-20 |
AU2001297631A8 (en) | 2005-09-15 |
WO2002065834A8 (fr) | 2003-06-26 |
WO2002065834A2 (fr) | 2002-08-29 |
JP2004518734A (ja) | 2004-06-24 |
CA2426811A1 (fr) | 2002-08-29 |
WO2002065834A3 (fr) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001297631A8 (en) | Novel formulations of carvedilol | |
HRP20030027A2 (en) | Carvedilol | |
IL142268A0 (en) | Ophthalmic formulations | |
HUP0303732A2 (en) | Hsa-free formulations of interferon-beta | |
GB0015490D0 (en) | Novel formulations | |
AU9473501A (en) | Stabilization of solid drug formulations | |
HUP0201220A3 (en) | Adjuvant combination formulations | |
HUP0204417A3 (en) | Oral ciprofloxacin-composition of controlled release | |
GB0009612D0 (en) | Therapeutic formulations | |
GB9923045D0 (en) | New oral formulations | |
GB0009609D0 (en) | Therapeutic compositions | |
GB0030857D0 (en) | Therapeutic compositions | |
HUP0600589A2 (en) | Adjuvant combination formulations | |
GB0012718D0 (en) | Conjugates of aminodrugs | |
GB0115893D0 (en) | Formulations | |
AU2002341923A1 (en) | Novel formulations of carvedilol | |
GB9911823D0 (en) | New vaccine formulations | |
GB0116403D0 (en) | Novel Formulations | |
GB0022027D0 (en) | Disfectant formulations | |
TW479920U (en) | Improvement of socket | |
GB9909079D0 (en) | Novel formulations | |
GB9909080D0 (en) | Novel formulations | |
NZ513664A (en) | Long acting formulations | |
GB0107226D0 (en) | Formulations | |
GB0008029D0 (en) | New vaccine formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030519 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050523 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/403 B Ipc: 7A 61K 9/62 B Ipc: 7A 61K 9/58 B Ipc: 7A 61K 9/52 B Ipc: 7A 61K 9/30 B Ipc: 7A 61K 9/26 B Ipc: 7A 61K 9/22 A |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070430 |